Key Highlights
- Full-year 2026 Revenue is now seen at USD 204 million to USD 206 million, above the earlier band of USD 200 million to USD 205 million.
- Q3 sales of about USD 49 million outran management's own USD 46 million to USD 48 million range.
- The fourth-quarter forecast is USD 48 million to USD 50 million in revenue, with adjusted EBITDA between zero and USD 1 million.
- Management restated its aim of positive Operating Cash Flow in the fourth quarter, a milestone in the turnaround.
Third-Quarter Results Shift Attention to the Final Quarter
Amwell (NYSE:AMWL) booked roughly USD 49 million of third-quarter revenue, ahead of its own range, while the raised forecast drew attention during a choppy session on November 17, 2026. Subscription income came in at USD 23.9 million, and visit revenue at its medical group reached USD 23.7 million, with close to 800,000 visits processed and a 53% gross margin. The company stayed unprofitable, with its net loss near USD 11 million and adjusted EBITDA at minus USD 3.6 million, both deeper than in the second quarter. Full-year guidance now contemplates adjusted EBITDA shortfalls of USD 7 million to USD 8 million, within a tighter bracket. The fourth quarter is the decisive period, since it suggests breakeven or slightly positive adjusted EBITDA for the first time during this restructuring. Visit revenue gives the Business a second income stream alongside its subscriptions.
An Enterprise Software Pivot Drives the Turnaround
Amwell (NYSE:AMWL) has spent years reducing costs and focusing on enterprise software sold to health systems and health plans, stepping back from the consumer telehealth Volume that surged during the Pandemic and later faded. That approach means lower sales but a clearer path to profit. Roughly 50 health-plan programmes covering more than 90 million lives, along with about 80 health systems, form a broad installed base. The medical group delivers clinical services that generate visit revenue, including work for government clients. A key uncertainty is the Defense Health Agency, a substantial customer whose contract terms beyond the third quarter of 2026 are not yet firm on a comparable basis. Any reduction would hit revenue and delay positive cash flow, so investors are watching closely. Growth in subscription income from health systems and plans would offset that exposure and improve Earnings quality. Investors will therefore read the fourth-quarter numbers alongside any update on that contract. Management's guidance framework means the next release will test every element of this outlook.
Breakeven Goal Meets Contract and Payer Headwinds
For Amwell (NYSE:AMWL), the fourth-quarter report due early in 2027 will show whether breakeven and positive operating cash flow were reached. Success would mark a turning point and could alter how investors price a company that has behaved like a cash-burning small cap. Risks include reliance on a handful of customers, pricing pressure across digital health, and slow decision-making at hospitals and insurers with strained budgets. Health insurers dropped on November 17 after regulators proposed broader Medicare Advantage audits, underlining the financial strain on payers. The broad market was soft too, as the S&P 500 retreated 1.03% while the Russell 2000 gave up 1.50%, a climate that typically weighs on small unprofitable Growth Stocks whatever their progress. Such an environment tends to weigh on smaller unprofitable companies, regardless of how their operations are progressing. Government-facing work therefore carries contract-specific terms that investors track closely.
Where Things Stand
Amwell (NYSE:AMWL) can meet its raised USD 204 million to USD 206 million forecast only if fourth-quarter adjusted EBITDA reaches breakeven and operating cash flow turns positive, while its government contract holds. Investors will watch both milestones closely. A slip on either front would be read as a setback for the turnaround.






Please wait processing your request...